Abstract
Local consolidative therapy (LCT)has been confirmed to improve the overall survival of patients with non-small cell lung cancer (NSCLC) receiving targeted therapy and continuation of target therapy is currently recommended. it is unknown whether patients could benefit from targeted therapy holiday if no visible lesions and negative minimal residual disease (MRD) after LCT.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
